Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. The company was founded in 2017 and is headquartered in Chicago, Illinois.
Stock data | 2024 | Change |
---|---|---|
Price | $0.2801 | N/A |
Market Cap | $5.75M | N/A |
Shares Outstanding | 20.52M | N/A |
Employees | 7.00 | N/A |